Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Samantha Sharpe

Nurse Practitioner, Psychiatric/Mental Health Houston, TX Nurse Practitioner

NPI 1952992299 CMS profile 10872544

1110 Nasa Pkwy Ste 620, Houston, TX 77058

Open in the dashboard

General payments

$13,879

900 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Sharpe of Houston, TX is reported in the CMS Open Payments database as having received $13,879 across 900 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,931 266
2024 General $2,676 174
2023 General $3,324 217
2022 General $2,528 162
2021 General $1,420 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Sharpe
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Samantha Sharpe were reported at $3,931. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Samantha Sharpe Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,420 $166 $54–$482 $132
2022 $2,528 $195 $66–$559 $149
2023 $3,324 $233 $82–$673 $160
2024 $2,676 $236 $84–$688 $164
2025 $3,931 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,782 117 payments
  2. Otsuka America Pharmaceutical, Inc. $1,081 53 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,077 65 payments
  4. AbbVie, Inc. $1,000 86 payments
  5. Neurocrine Biosciences, Inc. $903 35 payments
  6. Teva Pharmaceuticals USA, Inc. $877 52 payments
  7. Axsome Therapeutics, Inc. $860 44 payments
  8. Supernus Pharmaceuticals, Inc. $741 66 payments
  9. Neos Therapeutics, LP $730 65 payments
  10. Janssen Pharmaceuticals, Inc $633 45 payments
  11. Other $4,196 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,822 898 payments
  2. Education $57 2 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $1,174 75 payments
  2. TRINTELLIX $1,077 65 payments
  3. Auvelity $860 44 payments
  4. REXULTI $752 36 payments
  5. INGREZZA $638 24 payments
  6. CAPLYTA Psychiatry $607 42 payments
  7. VRAYLAR $605 59 payments
  8. LYBALVI $508 25 payments
  9. FANAPT $469 25 payments
  10. AUSTEDO $440 25 payments
  11. Other $9,033 585 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

25

Median for Nurse Practitioner: 389

Drug cost

$325

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trazodone Hcl Generic 14 $191
Escitalopram Oxalate Generic 11 $134

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$449 — —
Qelbree
$286 — —
TRINTELLIX
$241 — —
VRAYLAR
$212 — —
REXULTI
$203 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

900 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record